Early intravitreal bevacizumab for non-ischaemic branch retinal vein occlusion

Ophthalmologica

Volumn 223, Issue 2, 2009, Pages 124-127

  Rensch, Florian ^a   Jonas, Jost B ^a,b   Spandau, Ulrich H M ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Intravitreal bevacizumab; Macular oedema; Non ischaemic branch retinal vein occlusion

Indexed keywords

BEVACIZUMAB;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MALE; OPTICAL COHERENCE TOMOGRAPHY; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA MACULA EDEMA; RETINA VEIN OCCLUSION; VISUAL ACUITY;

EID: 57649094780     PISSN: 00303755     EISSN: None     Source Type: Journal    
DOI: 10.1159/000183844     Document Type: Article

References (12)

1. Cugati S, Wang JJ, Knudtson MD, Rochtchina E, Klein BE, Wong TY, Mitchell P: Retinal vein occlusion and vascular mortality: pooled data analysis of 2 population-based cohorts. Ophthalmology 2007;114:520-524.
2. Argon laser photocoagulation for macular edema in branch vein occlusion. The Branch Vein Occlusion Study Group. Am J Ophthalmol 1984;98:271-282.
3. Iturralde D, Spaide RF, Meyerle CB, Klancnik JM, Yannuzzi LA, Fisher YL, Sorenson J, Slakter JS, Freund KB, Cooney M, Fine HF: Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 2006;26:279-284.
4. Jaissle GB, Ziemssen F, Petermeier K, Szuman P, Ladewig M, Gelisken F, Völker M, Holz FG, Nartz-Schmidt KU: Bevacizumab zur Therapie des sekundären Makulaödems nach venösen Gefässverschlüssen. Ophthalmologe 2006;103:471-475.
5. Rosenfeld PJ, Fung AE, Puliafito CA: Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2006;36:336-339.
6. Spandau UH, Wickenhauser A, Rensch F, Jonas JB: Intravitreal bevacizumab for branch retinal vein occlusion. Acta Ophthalmol 2007;85:118-119.
7. Rabena MD, Pieramici DJ, Castellarin AA, Nasir MA, Avery RL: Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina 2007;27:419-425.
8. Costa RA, Jorge R, Calucci D, Melo LA Jr, Cardillo JA, Scott IU: Intravitreal bevacizumab (Avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina 2007;27:141-149.
9. Matsumoto Y, Freund KB, Peiretti E, Cooney MJ, Ferrara DC, Xannuzzi LA: Rebound macular edema following bevacizumab (Avastin) therapy for retinal venous occlusive disease. Retina 2007;27:426-431.
10. Noma H, Funatsu H, Yamasaki M, Tsukamoto H, Mimura T, Sone T, Jian K, Sakamoto I, Nakano K, Yamashita H, Minamoto A, Mishima HK: Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am J Ophthalmol 2005;140:256-261.
11. Pai SA, Shetty R, Vijayan PB, Venkatasubramanian G, Yadav NK, Shetty BK, Babu RB, Narayana KM: Clinical, anatomic and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. Am J Ophthalmol 2007;143:601-606.
12. Manzano RP, Peyman GA, Khan P, Kivilcim M: Testing intravitreal toxicity of bevacizumab (Avastin). Retina 2006;26:257-261.